KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort.

Young Bae Sohn, Aram Yang, Min-Sun Kim, Jinsup Kim, Jae Seong Kim, Youngsin Oh, Dong-Kyu Jin

Genet Med 27(8) 101460

PMID40411345
PMCID-
DOI10.1016/j.gim.2025.101460
发表日期2025-05-24
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: To investigate the efficacy and safety of idursulfase beta (0.5 mg/kg weekly) in the treatment of mucopolysaccharidosis II, compared with a historical placebo from a previous idursulfase trial (TKT024). METHODS: The study comprised 2 sequential parts. In part 1, a randomized, double-blind study, idursulfase or idursulfase beta were given for 52 weeks. In the open, single-cohort part 2 study, additional participants received idursulfase beta for 52 weeks. Data from the idursulfase beta groups from parts 1 and 2 were pooled for comparisons with the historical placebo group (n = 32). The primary end point was a change in the 6-minute walk test at week 53. RESULTS: Participants in the idursulfase beta groups (n = 24) were male Asians (mean age, 12.0 years). Idursulfase beta was superior to placebo in 6-minute walk test improvement (62.2 vs 7.3 m, P < .0001). Decrease in urine glycosaminoglycan excretion (-71.13% vs 21.39%, P < .0001) and reduction in the liver (-26.67% vs -0.80%, P < .0001) and spleen volumes (-26.46% vs 7.2%, P < .0001) were significant. The safety profile of idursulfase beta was satisfactory. CONCLUSION: Idursulfase beta is a safe and effective treatment option in mucopolysaccharidosis II, addressing crucial somatic ailments presented by patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。